[
  {
    "ts": null,
    "headline": "Polen Global Growth's Q3 2025 Portfolio: A Mix Of Durable Earnings Growth And Conviction",
    "summary": "Polen Capital reviews Q3 2025 portfolio performance, AI-led positioning, and new holdings. Explore their long-term growth strategy and conviction-led decisions.",
    "url": "https://finnhub.io/api/news?id=503b208780459242c6de944553267988ba00739733a37f55880db9e343d347d6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761597000,
      "headline": "Polen Global Growth's Q3 2025 Portfolio: A Mix Of Durable Earnings Growth And Conviction",
      "id": 137232713,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160051571/image_1160051571.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Polen Capital reviews Q3 2025 portfolio performance, AI-led positioning, and new holdings. Explore their long-term growth strategy and conviction-led decisions.",
      "url": "https://finnhub.io/api/news?id=503b208780459242c6de944553267988ba00739733a37f55880db9e343d347d6"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=65f306876d616797782ad16bed3351e48b17e03a2a06fe6bf3bedc10a3067b8c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761582960,
      "headline": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "id": 137252040,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=65f306876d616797782ad16bed3351e48b17e03a2a06fe6bf3bedc10a3067b8c"
    }
  },
  {
    "ts": null,
    "headline": "United States Nebulizer Market Research 2025-2033, Competitive Analysis of OMRON, GE Healthcare, Boston Scientific, Koninklijke Philips, Vectura, Aerogen, DeVilbiss Healthcare, Beurer",
    "summary": "The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory diseases, advancements in nebulizer technology, and an increased focus on home healthcare solutions. Nebulizers offer effective inhalation therapy for conditions like asthma, COPD, and cystic fibrosis. Technological improvements such as smart connectivity and portable designs enhance user convenience,",
    "url": "https://finnhub.io/api/news?id=6ac04cf70edbfaa6f9b3f244f66af275e14e2eca8b5b971f77738cae845f7165",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761580080,
      "headline": "United States Nebulizer Market Research 2025-2033, Competitive Analysis of OMRON, GE Healthcare, Boston Scientific, Koninklijke Philips, Vectura, Aerogen, DeVilbiss Healthcare, Beurer",
      "id": 137228773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The United States nebulizer market is set to grow from US$ 466.55 million in 2024 to US$ 730.62 million by 2033, with a CAGR of 5.11%. This growth is driven by the rising prevalence of respiratory diseases, advancements in nebulizer technology, and an increased focus on home healthcare solutions. Nebulizers offer effective inhalation therapy for conditions like asthma, COPD, and cystic fibrosis. Technological improvements such as smart connectivity and portable designs enhance user convenience,",
      "url": "https://finnhub.io/api/news?id=6ac04cf70edbfaa6f9b3f244f66af275e14e2eca8b5b971f77738cae845f7165"
    }
  },
  {
    "ts": null,
    "headline": "PAHC vs. BSX: Which Stock Is the Better Value Option?",
    "summary": "PAHC vs. BSX: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=5d2d1266d63137867dacc418b82013c69dc9193772dab0e63576b14ad817638a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761579602,
      "headline": "PAHC vs. BSX: Which Stock Is the Better Value Option?",
      "id": 137231071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "PAHC vs. BSX: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=5d2d1266d63137867dacc418b82013c69dc9193772dab0e63576b14ad817638a"
    }
  },
  {
    "ts": null,
    "headline": "RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised",
    "summary": "Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.",
    "url": "https://finnhub.io/api/news?id=a7ce7df3664423c5eaf98f067d3a7b3097c0947f6abfe0f103e1bd0fc6813e56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573900,
      "headline": "RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised",
      "id": 137228774,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Revvity beats on Q3 earnings and raises 2025 EPS view, as balanced segment performance offsets margin pressure.",
      "url": "https://finnhub.io/api/news?id=a7ce7df3664423c5eaf98f067d3a7b3097c0947f6abfe0f103e1bd0fc6813e56"
    }
  },
  {
    "ts": null,
    "headline": "Does Boston Scientific (BSX) Have the Potential to Rally 25.61% as Wall Street Analysts Expect?",
    "summary": "The consensus price target hints at a 25.6% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
    "url": "https://finnhub.io/api/news?id=14f0f3dbf94b13f28ebb196852ce37ff68ec0c89de8553e203c29a29fe04a885",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573302,
      "headline": "Does Boston Scientific (BSX) Have the Potential to Rally 25.61% as Wall Street Analysts Expect?",
      "id": 137228775,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The consensus price target hints at a 25.6% upside potential for Boston Scientific (BSX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
      "url": "https://finnhub.io/api/news?id=14f0f3dbf94b13f28ebb196852ce37ff68ec0c89de8553e203c29a29fe04a885"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q3 2025 Top Contributors And Detractors",
    "summary": "Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Read more here.",
    "url": "https://finnhub.io/api/news?id=a14837d187021f8fee8db86afc8e31cb5f3c8ed677257bf29ae1ec7d698e180c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571620,
      "headline": "Baron Health Care Fund Q3 2025 Top Contributors And Detractors",
      "id": 137230524,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2195580261/image_2195580261.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Read more here.",
      "url": "https://finnhub.io/api/news?id=a14837d187021f8fee8db86afc8e31cb5f3c8ed677257bf29ae1ec7d698e180c"
    }
  },
  {
    "ts": null,
    "headline": "Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?",
    "summary": "GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.",
    "url": "https://finnhub.io/api/news?id=ac34a48efd20f64ed982bb938590cde25af7c4f99bff94c8c9d5081092d173db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761571200,
      "headline": "Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?",
      "id": 137228776,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "GE HealthCare's Q3 results are expected to show steady growth from Imaging and Diagnostics, though tariffs may weigh on margins and EPS.",
      "url": "https://finnhub.io/api/news?id=ac34a48efd20f64ed982bb938590cde25af7c4f99bff94c8c9d5081092d173db"
    }
  },
  {
    "ts": null,
    "headline": "Cardiovascular Repair & Reconstruction Devices - Global Market Forecast (2025-2032) Featuring Profiles of Medtronic, Edwards Lifesciences, Abbott Labs, Boston Scientific, Terumo and More",
    "summary": "The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The \"Card",
    "url": "https://finnhub.io/api/news?id=b58be3d3795a99203330d36b0797f29aec86fe493585c681251eab4e7c1eb01f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761568200,
      "headline": "Cardiovascular Repair & Reconstruction Devices - Global Market Forecast (2025-2032) Featuring Profiles of Medtronic, Edwards Lifesciences, Abbott Labs, Boston Scientific, Terumo and More",
      "id": 137228658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The \"Card",
      "url": "https://finnhub.io/api/news?id=b58be3d3795a99203330d36b0797f29aec86fe493585c681251eab4e7c1eb01f"
    }
  }
]